Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2006-11-07
2006-11-07
Huff, Sheela (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
C424S184100, C514S002600
Reexamination Certificate
active
07132109
ABSTRACT:
The present invention provides for a method of using heat shock proteins (HSPs) to amplify the immune response initiated by a vaccine. HSPs can be introduced into a subject before, concurrently, or after the administration of a vaccine. The HSPs can also be used to activate antigen presenting cells which are then introduced into a subject in conjunction with a vaccine. The HSPs used in the methods of the invention can be unbound or can be covalently or noncovalently bound to a peptide that is unrelated to the vaccine. The subject is preferably mammalian, and most preferably human. It is shown by way of example herein that HSPs induces secretion of cytokines and surface expression of antigen-presenting and co-stimulatory molecules. The invention also encompasses methods of treatment and prevention of cancer and infectious diseases in a subject.
REFERENCES:
patent: 5750119 (1998-05-01), Srivastava
patent: 5830464 (1998-11-01), Srivastava
patent: 5837251 (1998-11-01), Srivastava
patent: 5935576 (1999-08-01), Srivastava
patent: 5961979 (1999-10-01), Srivastava
patent: 5985270 (1999-11-01), Srivastava
patent: 5997873 (1999-12-01), Srivastava
patent: 6017540 (2000-01-01), Srivastava
patent: 6030618 (2000-02-01), Srivastava
patent: 6048530 (2000-04-01), Srivastava
patent: WO 97/06821 (1997-02-01), None
patent: WO 02/32923 (2002-04-01), None
Evans et al (Q. J. Med 1999;92:299-307).
Chen et al (Cancer Res. Feb. 15, 2000;60(4):1035-1042).
Yang et al (Int. J. Cancer Nov. 12, 1999;83(4):532-40).
Breloer et al J. Immunol Mar. 15, 1999;162(6):3141-7.
Merriam-Webster Online (www.m-w.com).
U.S. Appl. No. 60/377,483, filed May 2, 2002, Srivastava.
U.S. Appl. No. 60/377,484, filed May 2, 2002, Srivastava.
U.S. Appl. No. 10/126,368, filed Apr. 19, 2002, Srivastava.
U.S. Appl. No. 10/131,937, filed Apr. 25, 2002, Srivastava.
U.S. Appl. No. 10/131,961, filed Apr. 25, 2002, Srivastava.
Andersen P., 1994, Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun. 62(6):2536-44.
Anthony et al., 1999, Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule. Vaccine 28;17(4):373-83.
Asea et al., 2000, HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nature Medicine 6:435-442.
Banchereau et al., 1998, Dendritic cells and the control of immunity. Nature 392:245-252. Review.
Barrios et al., 1992, Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants andBacillus calmetteGuerin priming. Eur J Immunol. 22(6):1365-72.
Barrios et al., 1994, Heat shock proteins as carrier molecules: in vivo helper effect mediated byEscherichia coliGroEL and Dna K proteins requires cross-linking with antigen. Clin Exp Immunol. 98(2):229-33.
Basu et al., 2000, Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cell and activate the NF-kappa B pathway. Int Immunol. 12(11):1539-46.
Basu S, et al., 2001, CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity. 14(3):303-13.
Blander SJ, Horwitz MA., 1993, Major cytoplasmic membrane protein ofLegionella pneumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionaires' disease. J Clin Invest. 91(2):717-23.
Breloer et al., 1999, In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins. J. Immunol. 162:3141-3147.
Chen et al., 1999, Human 60-kDa heat-shock protein: a danger signal to the innate immune system. J. Immunol. 162:3212-3219.
Craig, 1993, Chaperones: helpers along the pathways to protein folding. Science 260:1902-1903.
Del Giudice G., 1994, Hsp70: a carrier molecule with built-in adjuvanticity. Experientia 30;50(11-12):1061-6. Review.
Feng et al., Apr. 6-10, 2002, Exogenous heat shock proteins provide adjuvant effects on enhancing the immunogenicity of apoptotic tumor cells and inducing antitumor immunity. AACR 93rdAnnual Meeting, vol. 43, Abstract #2214.
Ferrero et al., 1995, The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc. Natl Acad Sci U S A. 3;92(14):6499-503.
Gallucci et al., 1999, Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5:1249-55.
Gelber et al., 1994, Vaccination with pureMycobacterium lepraeproteins inhibitsM. lepraemultiplication in mouse footpads. Infect. Immun. 62(10):4250-5.
Gelber et al., 1992, Vaccination of mice with a soluble protein fraction ofMycobacterium lepraeprovides consistent and long-term protection againstM. lepraeinfection. Infect Immun. 60(5):1840-4.
Gething, et al. Protein folding in the cell. Nature 1992 355:33-45. Review.
Gomez et al., 1991, Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane ofHistoplasma capsulatumyeast cells. Infect Immun. 59(12):4459-64.
Gomez et al., 1995, Vaccination with recombinant heat shock protein 60 fromHistoplasma capsulatumprotects mice against pulmonary histoplasmosis. Infect Immun. 63(7):2587-95.
Gomez et al., 1992, An 80-kilodalton antigen fromHistoplasma capsulatumthat has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice. Infect Immun. 60(7):2565-71.
Horwitz et al., 1995, Protective immunity against tuberculosis induced by vaccination with major extracellular proteins ofMycobacterium tuberculosis.Proc Natl Acad Sci U S A. 92(5):1530-4.
Hubbard et al., 1992, Immunization of mice with mycobacterial culture filtrate proteins. Clin Exp Immunol. 87(1):94-8.
Janeway et al. (editors), Immuno Biology—The Immune System in Health and Disease, 3rdEd., Chapter 7-6, Garland Publishing Inc. New York and London (1997).
Jordan Report, 2002, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States.
Kojima et al., Apr. 6-10, 2002, Combination therapy of tumor-derived gp96 and GM-CSF or IL-12-gene transduced tumor cells in the control of LLC tumor. AACR 93rdAnnual Meeting, vol. 43, Abstract #5516.
Lindquist et al., 1988, The heat-shock proteins. Annu. Rev. Genetics 22:631-677. Review.
Lowrie et al., 1994, Towards a DNA vaccine against tuberculosis. Vaccine 12(16):1537-40. Review.
Lussow et al., 1991, Mycobacterial heat-shock proteins as carrier molecules. Eur J Immunol. 21(10):2297-302.
Melcher et al., 1998, Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med. 5:581-7.
Menoret et al., 1995, Co-segregation of tumor immunogenicity with expression of inducible but not constitutive hsp70 in rat colon carcinomas. J. Immunol. 155:740-7.
Mizzen, 1998, Immune responses to stress proteins: applications to infectious disease and cancer. Biotherapy 10:173-185. Review.
Ohashi et al., 2000, Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J. Immunol. 164:558-561.
Pal P.G., Horwitz M.A., 1992, Immunization with extracellular proteins ofMycobacterium tuberculosisinduces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect Immun. 60(11):4781-92.
Pardoll, 2000, Therapeutic vaccination for cancer. Clin. Immunol. 95(1 Pt 2):S44-62.
Rescigno et al., 1998, Dendritic cell survival and maturation are regulated by different signaling pathways. J. Exp. Med. 188:2175-2180.
Sauter et al., 2000, Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191:423-434.
Silva C.L., Lowrie D.B., 1994, A single mycobacterial protein (hsp 65) expressed by a transgenic
Huff Sheela
Jones Day
University of Connecticut Health Center
Yaen C.
LandOfFree
Using heat shock proteins to increase immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Using heat shock proteins to increase immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Using heat shock proteins to increase immune response will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3654517